Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona 08028, Spain.
Unit of Synthesis and Biomedical Applications of Peptides, Department of Biological Chemistry, IQAC- CSIC, Jordi Girona 18, 08034, Barcelona, Spain.
Curr Med Chem. 2021;28(22):4356-4379. doi: 10.2174/0929867328666201209095753.
Vaginal drug delivery offers an opportunity for effective microbicide treatments. However, the physiological characteristics of the vagina represent a challenge when preparing microbicide formulations for local delivery that avoid systemic effects.
To review recent advances in vaginal microbicides placing special emphasis on nanocarriers that encapsulate peptide microbicides. The review includes an overview of local treatment and prevention strategies for bactericidal, fungal, protozoal and viral vaginal infections that use peptide microbicides.
Scientific literature and clinical trials published in the PubMed database since 2015 are analyzed.
Peptide microbicides are used for vaginal drug delivery as a means of prevention and treatment of several infectious diseases, especially sexually transmitted infections, and it is clear that such peptide-based microbicides constitute a suitable strategy. Their combination with nanotechnological drug delivery systems improves local peptide administration while avoiding their degradation and adverse effects. To date, only a few polymeric and lipid-based nanocarriers have been used for peptide microbicide vaginal delivery.
The combination of nanotechnology and peptide microbicides has emerged over recent years, and different platforms are being used for vaginal peptide delivery. Nanostructured systems for peptide delivery via vaginal rings or hydrogels are increasingly used as platforms capable of providing suitable drug delivery. However, there is still a lack of knowledge about nanocarriers aimed at encapsulating peptides for local microbicide delivery.
阴道给药为有效的杀微生物剂治疗提供了机会。然而,阴道的生理特征在为局部递送来避免全身作用的杀微生物剂制剂做准备时带来了挑战。
综述最近在阴道杀微生物剂方面的进展,特别强调包封肽杀微生物剂的纳米载体。该综述包括局部治疗和预防细菌性、真菌性、原虫性和病毒性阴道感染的策略,这些策略使用肽杀微生物剂。
分析了自 2015 年以来在 PubMed 数据库中发表的科学文献和临床试验。
肽杀微生物剂被用于阴道药物递送,作为预防和治疗几种传染病(尤其是性传播感染)的手段,很明显,基于肽的此类杀微生物剂构成了一种合适的策略。将它们与纳米技术药物递送系统结合可改善局部肽给药,同时避免其降解和不良反应。迄今为止,只有少数聚合和基于脂质的纳米载体被用于肽杀微生物剂阴道递送。
纳米技术和肽杀微生物剂的结合在近年来已经出现,并且正在使用不同的平台来进行阴道肽的传递。通过阴道环或水凝胶进行肽传递的纳米结构化系统越来越多地被用作能够提供合适药物递送的平台。然而,对于旨在用于局部杀微生物剂传递的纳米载体的知识仍然不足。